Section 232 Pharma Country-Tier Substitution Economics: EU 15 Percent vs India 110 Percent Stack

The Section 232 pharma proclamation of April 2 2026 established a tiered rate structure that creates a landed-cost gap between EU/Japan/Korea/Switzerland/Liechtenstein origin and unpreferred origins including India, China, Turkey, Vietnam, and most non-Annex-II jurisdictions. With Annex III companies hitting the July 31 effective date and everyone else facing September 29, this is the country-tier substitution economics walkthrough for pharma importers modeling supplier restructuring.

The country tier structure recap

The tiers cut across the Section 232 pharma framework independent of the Annex II or III company-level assignment:

• Products of the European Union, Japan, South Korea, Switzerland, and Liechtenstein: 15 percent
• Products of the United Kingdom: 10 percent (with mechanism to fall to zero via bilateral pricing agreement)
• Companies operating under an approved onshoring plan: 20 percent through April 30 2030
• Everyone else: 100 percent
• Annex II companies (13 firms with pre-April-2 MFN agreements): exempt through January 20 2029
• Annex IV specialty products (orphan drugs, biosimilars, generics, nuclear medicines, plasma, fertility, cell/gene therapies, ADCs, CBRN countermeasures, animal health): exempt entirely

The tier cascade is applied in this order: exempt-product check first (Annex IV), then exempt-company check (Annex II), then approved onshoring plan (20 percent), then country-tier assignment (15 percent or 10 percent for preferred origins), then default 100 percent.

The stacking math on a single covered API

Worked example on a 500,000 USD entry line for a covered patented API classified under Chapter 29 (2941.90.10 or similar) that is patent-covered, not orphan-designated, not on Annex II, no onshoring plan:

• EU origin: base HTSUS duty 0 percent + Section 232 pharma layer 15 percent = 15 percent = 75,000 USD additional duty
• Japan origin: same 15 percent = 75,000 USD additional duty
• Korea origin: same 15 percent = 75,000 USD additional duty
• Switzerland origin: same 15 percent = 75,000 USD additional duty
• UK origin: 10 percent = 50,000 USD additional duty
• India origin: 100 percent Section 232 + 10 percent Section 301 forced-labor layer = 110 percent = 550,000 USD additional duty
• China origin: 100 percent Section 232 + 12.5 percent Section 301 forced-labor layer + any Section 301 List 3 or 4A layer already applicable = 112.5 percent plus = 562,500 USD plus additional duty
• Turkey origin: 100 percent Section 232 + 10 percent Section 301 forced-labor layer (Turkey is in the 10 percent tier) = 110 percent = 550,000 USD additional duty
• Vietnam origin: 100 percent Section 232 + 10 percent Section 301 forced-labor layer = 110 percent = 550,000 USD additional duty

The delta between EU sourcing at 75,000 USD and India sourcing at 550,000 USD on the single entry is 475,000 USD in favor of EU sourcing.

Annualized on 6 million USD volume (medium-scale specialty pharma program), the delta is 5.7 million USD per year in favor of EU sourcing over Indian sourcing on the same covered patented API.

The generic exemption changes the calculation entirely

If the same 500,000 USD entry line is a generic API (Orange Book generic listing or Purple Book biosimilar listing), the Section 232 pharma layer is zero regardless of country of origin.

Worked example on the same 500,000 USD entry line as a generic:

• EU origin: 0 percent Section 232 layer = 0 USD additional duty
• India origin: 0 percent Section 232 layer + 10 percent Section 301 forced-labor layer = 10 percent = 50,000 USD additional duty
• China origin: 0 percent Section 232 + 12.5 percent Section 301 + Section 301 List 3 or 4A as applicable = 12.5 percent plus = 62,500 USD plus additional duty

The generic exemption collapses the country-tier gap. For generic API programs, Indian sourcing is still 50,000 USD more expensive per 500,000 USD entry than EU sourcing (from the Section 301 forced-labor layer), but the 475,000 USD gap that opens for patented products does not apply.

The read for pharma importers: SKU-level classification between patented and generic is the operative decision variable. Patented programs face the full country-tier substitution economics pressure. Generic programs face only the Section 301 forced-labor layer differential.

Substantial transformation and the country-of-origin test

Country-of-origin for the Section 232 pharma layer is anchored on the country of substantial transformation, not the country of first packaging or country of export. This has real operational consequences on multi-country pharma supply chains.

Typical multi-country patterns:

• API manufactured in India, formulated into finished dose in Ireland, packaged in the Netherlands, exported to the US: the finished dose has substantial transformation at Ireland (formulation step is generally the substantial transformation moment for finished pharmaceuticals). Country of origin for the finished dose import is Ireland (EU), and the 15 percent tier applies. The API import from India to Ireland is a separate transaction at the Indian country-of-origin.
• API manufactured in China, formulated into finished dose in India, exported to the US: substantial transformation at India means country of origin for the finished dose import is India, and the 100 percent tier applies plus the 10 percent Section 301 forced-labor layer.
• API manufactured in China, formulated into finished dose in Switzerland, exported to the US: substantial transformation at Switzerland means 15 percent tier applies.
• API manufactured in India, imported as API for use in US finishing: two separate transactions, the API import from India hits the 100 percent tier plus 10 percent Section 301, but the US-finished product is US-origin and not exposed to the Section 232 pharma layer on the finished-dose transaction (there is none because it is not imported).

The pattern shows that formulation-side moves (bringing formulation into the EU or moving formulation to a preferred-tier country) can be a faster substitution play than API-side moves (finding a new API supplier in the EU takes years to qualify). US-side formulation growth is also economically favored on this framework.

The 60-day compliance runway realistic scope

For non-Annex-III importers with September 29 effective date, the 60-day runway between July 31 and September 29 is administrative-preparation time, not physical-supply-chain-restructuring time.

Pharma supplier qualification cycles typically run:

• 6 to 12 months for API sourcing changes on established suppliers with existing GMP documentation
• 12 to 24 months for API sourcing changes involving new suppliers requiring FDA facility inspection
• 12 to 36 months for finished-dose sourcing changes involving reformulation or stability testing
• 3 to 6 months for country-of-origin routing changes on existing supplier networks

Realistic scope for the 60-day window:

• Full SKU cross-walk against Annex I HTS list
• Country-of-substantial-transformation verification on every covered SKU
• Patent-status audit against FDA Orange Book and Purple Book for each covered SKU
• Annex II or III company-tier verification for every legal entity in the corporate family
• MFN pricing agreement negotiation initiation with HHS
• Onshoring plan preparation for Commerce submission
• Broker Chapter 99 filing workflow configuration
• Customs bond sizing update
• Cash flow forecast update
• Customer contract price pass-through language review
• PBM and payer contract price adjustment discussions

The 60-day window is enough for the administrative preparation but not for the physical supply chain restructuring. Substitution economics play out over 2027 through 2029 as supplier qualification cycles complete and the deferred sourcing decisions materialize.

The MFN and onshoring deal pathways

Two pathways cut the rate for non-preferred-country sourcing:

MFN pricing agreement with HHS. Companies that execute an MFN agreement gain duty exemption through January 20 2029 if they are on Annex II. Companies not on Annex II can negotiate MFN agreements that reduce the additional 20 percent onshoring plan surcharge but do not eliminate the base 100 percent rate. The MFN agreement pathway is primarily a pricing concession, not a duty pathway, for non-Annex-II companies.

Onshoring plan approval by Commerce. Companies with an approved onshoring plan pay 20 percent through April 30 2030 instead of 100 percent. Onshoring plans require Commerce approval against forthcoming Federal Register criteria (not yet published as of the July 31 effective date). Once criteria publish, importers can submit plans for Commerce review. Approval timelines are uncertain but likely 3 to 6 months from submission based on precedent from other Section 232 exemption processes.

The economic value of the onshoring plan pathway is the 80 percentage point rate reduction (100 percent to 20 percent) which on a 500,000 USD entry is 400,000 USD in avoided duty. Annualized on 6 million USD volume, the value is 4.8 million USD per year in avoided duty against the compliance and physical-onshoring investment required for plan approval.

For companies with capital-intensive US production capacity already in place or planned, the onshoring plan is likely the fastest path to rate reduction. For companies without US capacity and without near-term investment plans, the MFN pathway or country-tier substitution are the operative levers.

The read for pharma importers this week

• Annex III companies (17 named firms): day-one enforcement is live as of July 31 12:01 AM ET. Broker configuration should be complete or completing today. First entries at the 100 percent tier are landing this morning.
• Non-Annex-III companies with covered patented SKUs: 60 days to complete the administrative preparation. Priority the SKU cross-walk and the MFN/onshoring pathway evaluation.
• Companies with only generic and biosimilar SKUs: no direct Section 232 pharma exposure but Section 301 forced-labor layer applies where country of origin is in the 60-economy list.
• Companies with EU/Japan/Korea/Swiss/Liechtenstein sourcing on covered patented SKUs: the 15 percent tier applies and the substitution economics favor holding that sourcing. New Indian or Chinese sourcing decisions should reflect the 110 percent stack.